Clinical Features and Outcome of Multidrug-Resistant Osteoarticular Tuberculosis: A 12-Year Case Series from France

Author:

Bonnet Isabelle,Haddad ElieORCID,Guglielmetti Lorenzo,Bémer PascaleORCID,Bernard Louis,Bourgoin Anne,Brault Rachel,Catho Gaud,Caumes Eric,Escaut Lélia,Fourniols Eric,Fréchet-Jachym Mathilde,Gaudart Alice,Guillot Hélène,Lafon-Desmurs Barthélémy,Lanoix Jean-Philippe,Lanotte Philippe,Lemaignen AdrienORCID,Lemaire Bénédicte,Lemaitre Nadine,Michau Christophe,Morand Philippe,Mougari Faiza,Marigot-Outtandy Dhiba,Patrat-Delon SolèneORCID,Perpoint Thomas,Piau Caroline,Pourcher Valérie,Zarrouk Virginie,Zeller Valérie,Veziris Nicolas,Jauréguiberry Stéphane,Aubry AlexandraORCID

Abstract

The optimal treatment for osteoarticular infection due to multidrug-resistant tuberculosis strains (MDR-OATB) remains unclear. This study aims to evaluate the diagnosis, management and outcome of MDR-OATB in France. We present a case series of MDR-OATB patients reviewed at the French National Reference Center for Mycobacteria between 2007 and 2018. Medical history and clinical, microbiological, treatment and outcome data were collected. Twenty-three MDR-OATB cases were reported, representing 3% of all concurrent MDR-TB cases in France. Overall, 17 were male, and the median age was 32 years. Six patients were previously treated for TB, including four with first-line drugs. The most frequently affected site was the spine (n = 16). Bone and joint surgery were required in 12 patients. Twenty-one patients (91%) successfully completed the treatment with a regimen containing a mean of four drugs (range, 2–6) for a mean duration of 20 months (range, 13–27). Overall, high rates of treatment success were achieved following WHO MDR-TB treatment guidelines and individualized patient management recommendations by the French National TB Consilium. However, the optimal combination of drugs, duration of treatment and role of surgery in the management of MDR-OATB remains to be determined.

Publisher

MDPI AG

Subject

Virology,Microbiology (medical),Microbiology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3